Oncology Central

TAILORx: a practice-changing breast cancer trial

The TAILORx study has demonstrated that most women with a specific early-stage breast cancer and midrange score on the Oncotype DX® test do not need chemotherapy after surgery. These findings will spare thousands of women from the harmful effects of chemotherapy. In this interview we speak with Andrew Paramore from Genomic Health (CA, USA) to discover insider details of the trial and what’s next for TAILORx.

If you would like to read the news surrounding TAILORx, click here.

Interested in discovering other key ASCO talks? Discover our highlights here.


Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.